We've officially opened our newest office in Philadelphia in order to be situated in the heart of the healthcare and pharmaceutical industry. As HLG’s engagement in healthcare and pharmaceuticals deepens, the Philadelphia office affords HLG increased opportunity to serve its clients as the industry undergoes profound change. The Philadelphia location will be managed by a senior leader with extensive experience in healthcare, government, and corporate affairs.


Philadelphia, PA – Today, High Lantern Group, a strategy and communications consulting firm with offices across the country, officially opened its newest office in Philadelphia in order to continue to meet the demands of the growing pharmaceutical and healthcare client base.  The new office situates the rapidly expanding firm in the heart of the healthcare and pharmaceutical corridor. The tri-state region of Pennsylvania, New Jersey, and Delaware is home to 80% of the U.S. pharmaceutical industry.

“The addition of the Philadelphia office marks a strategic expansion for High Lantern Group. It is a signal of our further engagement with the healthcare and pharmaceutical fields,” said Michael W. Hodin, PhD, Managing Partner at High Lantern Group. “We’re very excited about the opportunity. Our team has decades of experience in this sector, in both senior roles within global pharmaceutical organizations, government, advocacy organizations and in consulting capacities.”

The Philadelphia office will be High Lantern Group’s fourth U.S. office, adding to those located in New York, Los Angeles and Washington, D.C.  In addition, the Philadelphia office will provide clients with full access to the capabilities of the entire firm.

“Developing a more substantial presence in this region was a natural outgrowth of our work in the health and pharmaceutical industries,” said Drew Holzapfel, Managing Director at High Lantern Group. “The Philadelphia office will strengthen High Lantern Group’s ability to anticipate significant industry trends and respond to a changing public landscape.”

To begin, High Lantern Group’s Philadelphia office will be managed by Drew Holzapfel, Managing Partner, who, prior to joining High Lantern Group, spent two decades in pharmaceuticals and healthcare.  To open the office, Drew will be joined by Mark Hoffmann, PhD, Director, a tenured member of the High Lantern Group team who is relocating to be part of the Philadelphia leadership team. 
For more information about High Lantern Group, visit www.highlanterngroup.com or email Drew Holzapfel at dholzapfel@highlanterngroup.com.